Please ensure Javascript is enabled for purposes of website accessibility

Why Aurinia Pharmaceuticals Stock Is Crashing Today

By George Budwell - May 6, 2021 at 5:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Expectations for the biotech's first-quarter sales may have been too high.

What happened

Shares of Aurinia Pharmaceuticals (AUPH -2.08%), an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today.  

So what

Investors appear to be backing away from Aurinia today for one simple reason: Sales of the biotech's newly approved lupus nephritis medication Lupkynis (aka voclosporin) failed to break even $1 million during the first quarter of 2021. Wall Street, for its part, was expecting sales of approximately $1.1 million for the three-month period.

A worried man staring at his laptop while sitting at a desk.

Image source: Getty Images.

While these early sales figures obviously aren't great, investors may want to keep in mind that Lupkynis was approved less than five months ago during a global pandemic. In other words, this mass exodus by shareholders -- in response to these rather preliminary sales data -- probably isn't warranted. 

Now what

On the bright side, Aurinia still had a healthy $360.9 million in cash and cash equivalents at the end of the first quarter. That amount should give the company two more years to get Lupkynis' commercial launch on track. 

Should bargain hunters take advantage of this sizable pullback in Aurinia's share price? Lupkynis still has a real shot to break $1 billion in annual sales within the next two to three years. So, if you're in the market for a top growth stock, you might want to check out this beaten-down biotech following this post-earnings dip.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
AUPH
$8.00 (-2.08%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.